BS01 in Patients With Retinitis Pigmentosa

NCTID	NCT04278131 (View at clinicaltrials.gov)
Description	A Phase 1/2, Safety and Efficacy Trial of BS01, a Recombinant Adeno-Associated Virus Vector Expressing ChronosFP (AAV2-CAG-ChronosFP) in Patients with Retinitis Pigmentosa (Show More)
Development Status	Active
Indication	Retinitis Pigmentosa
Disease Ontology Term	DOID:10584
Compound Name	BS01
Compound Description	AAV2-CAG-ChronosFP-WPRE
Sponsor	Bionic Sight LLC
Funder Type	Industry
Recruitment Status	Recruiting (Click here for study contact information)
Enrollment Count	20 (ESTIMATED)
Results Posted	Not Available

Target Gene/Variant	ChronosFP
Therapy Type	Gene transfer
Therapy Route	In-vivo
Mechanism of Action	Overexpression of protective allele/gene
Route of Administration	Intravitreal
Drug Product Type	Viral vector
Target Tissue/Cell	Retinal ganglion
Delivery System	Viral transduction
Vector Type	AAV2
Dose 1	Dose escalation with 4 levels, unknown concentrations

Eligible Age	>=18 Years
Standard Ages	Adult, Older adult
Sexes Eligible for Study	ALL
Eligibility Criteria	Inclusion Criteria: * Confirmed diagnosis of retinitis pigmentosa * At least one eye with vision no better than 20/160 visual acuity on the EDTRS scale or, for patients with peripheral vision loss, a visual field no greater than 30°. Exclusion Criteria: * Prior receipt of any AAV gene therapy product * Large amplitude nystagmus View Inclusion and Exclusion Criteria at ClinicalTrials.gov

No.of Trial Sites	1
Locations	United States

Has US IND	True
FDA Designations	Regenerative Medicine Advanced Therapy
Recent Updates	Gene therapy product is coupled with a neural circuit, retinal prosthesis